News stories about Gilead Sciences (NASDAQ:GILD) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Gilead Sciences earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 45.1608579585764 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Here are some of the headlines that may have impacted Accern Sentiment Analysis’s rankings:

How to Become a New Pot Stock Millionaire

Gilead Sciences (NASDAQ:GILD) opened at $79.51 on Friday. Gilead Sciences has a fifty-two week low of $63.76 and a fifty-two week high of $89.54. The stock has a market capitalization of $106,238.41, a price-to-earnings ratio of 22.85, a PEG ratio of -1.86 and a beta of 1.24. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.74 and a quick ratio of 2.67.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.67 by $0.11. The firm had revenue of $5.95 billion for the quarter, compared to the consensus estimate of $5.71 billion. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The firm’s revenue for the quarter was down 18.7% on a year-over-year basis. During the same period in the previous year, the business earned $2.70 EPS. sell-side analysts anticipate that Gilead Sciences will post 6.21 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 29th. Investors of record on Friday, March 16th will be issued a $0.57 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date is Thursday, March 15th. This represents a $2.28 dividend on an annualized basis and a yield of 2.87%. Gilead Sciences’s dividend payout ratio is presently 59.77%.

GILD has been the topic of a number of recent analyst reports. Vetr cut Gilead Sciences from a “buy” rating to a “hold” rating and set a $91.25 target price on the stock. in a research note on Monday, January 29th. Citigroup raised Gilead Sciences from a “neutral” rating to a “buy” rating and reduced their target price for the company from $88.80 to $76.00 in a report on Tuesday, January 30th. Morgan Stanley reduced their target price on Gilead Sciences from $87.00 to $84.00 and set an “equal weight” rating for the company in a report on Wednesday, February 7th. Bank of America boosted their target price on Gilead Sciences from $82.00 to $87.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 7th. Finally, BMO Capital Markets boosted their price objective on Gilead Sciences from $86.00 to $88.00 and gave the company a “market perform” rating in a research report on Thursday, February 8th. One analyst has rated the stock with a sell rating, ten have given a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company. Gilead Sciences has a consensus rating of “Buy” and a consensus target price of $88.61.

In other news, insider John C. Martin sold 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $73.62, for a total value of $3,681,000.00. Following the completion of the sale, the insider now directly owns 3,046,766 shares in the company, valued at $224,302,912.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director John Francis Cogan sold 5,833 shares of the stock in a transaction that occurred on Monday, March 12th. The stock was sold at an average price of $80.93, for a total value of $472,064.69. The disclosure for this sale can be found here. Insiders sold a total of 430,268 shares of company stock valued at $34,074,395 in the last ninety days. 1.30% of the stock is currently owned by insiders.

TRADEMARK VIOLATION NOTICE: “Gilead Sciences (GILD) Given News Sentiment Score of 0.13” was originally published by Marea Informative and is owned by of Marea Informative. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Insider Buying and Selling by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with's FREE daily email newsletter.